Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

EU outlines measures to mitigate antibiotic shortage across Europe

An unseasonably early upsurge in respiratory infections has led to the increase in demand

- PMLiVE

EC launches cancer imaging initiative to accelerate innovation and early diagnosis

Researchers will have better access to high-quality resources and databases

- PMLiVE

Digital technology: a significant change in healthcare innovation

By Megan Allen

- PMLiVE

Neurodiversity and healthcare communications – do we know enough and do we do enough?

By Robert Goodwin

Virtual Steering Committee & Peer Influence Program

In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program.

Impetus Digital

- PMLiVE

Alzheimer’s Society urges UK government to deliver on dementia plan

The strategy, announced in May last year, includes doubling dementia research funding

- PMLiVE

Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

The investigational treatment regimen met its primary endpoint of overall survival

- PMLiVE

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

The BTK inhibitor demonstrated better results than Imbruvica, a standard of care treatment in CLL

- PMLiVE

Meeting healthcare’s rising challenges

The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential

- PMLiVE

Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality

By Stephen Jones, Heather Bennett and Agustin Ramirez

- PMLiVE

SCIRIS ACQUIRES SOURCE HEALTH ECONOMICS

Global healthcare communications company SCIRIS is delighted to announce the acquisition of UK-based Source Health Economics – an agency specialising in health economics and outcomes research (HEOR).The development is the...

Porterhouse Medical Group

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links